LeMaitre Vascular to Present at Upcoming Investor Conferences
BURLINGTON, Mass., Dec. 29, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in two investor...
Year: 2020
Osmotica Pharmaceuticals plc Receives Complete Response Letter from U.S. Food and Drug Administration for Arbaclofen Extended Release Tablets
BRIDGEWATER, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”) today announced that...
Predictive Oncology Announces Cancellation of Special Meeting in December 2020
Reincorporation Proposal Received Overwhelming Support Among Shares VotedNEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) (the...
Lui Franciosi Reviewing the Use of Sugar-Based Molecules as Potential Treatments for COVID-19
VANCOUVER, British Columbia, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Lui Franciosi is pleased to announce that Franciosi Consulting Ltd. will...
Eve & Co Announces Share Consolidation
TORONTO, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Eve & Co. Incorporated (TSXV: EVE) (OTCQX: EEVVF) (the “Company” or “Eve &...
Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor
Sydney, AUSTRALIA, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology...
ClearPoint Neuro, Inc. Announces Funding of Additional $7.5M of Existing Convertible Note on Improved Terms
Represents Draw of Additional Proceeds from Petrichor Announced in January 2020IRVINE, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro,...
VAXIL Provides Update on USAMRIID and Oral Experiments
NESS-ZIONA, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative...
Assertio Announces Transfer of Listing from Nasdaq Global Select Market to Nasdaq Capital Market
Company Receives additional 180-day grace period, until June 28, 2021, to satisfy the $1.00 bid price requirement to maintain Nasdaq...
Emergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin (COVID-HIG) Product Candidate for Prophylaxis
GAITHERSBURG, Md. and NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) and Mount Sinai Health System...
Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference
PRINCETON, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on...
Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®
European Union orders 100 million additional doses of COMIRNATY® bringing total doses to 300 million for 27 EU member states...
Tauriga Sciences Inc. Completes Payment for the Entirety of its 3rd Production Run of its Gelatin Free, CBD Infused Gum Drop Product, Branded as: Tauri-Gummies
12_29 PR Snapshot of Tauri-Gummies™ EU Trademark The Company has Received Confirmation from its Contract Manufacturer, Concerning the Arrival of...
Satellite Healthcare Names Industry Veteran Jeffrey Goffman as CEO
SAN JOSE, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Satellite Healthcare, the leading nonprofit dialysis provider, today announced Jeffrey Goffman...
LifeLabs surpasses 1 million COVID-19 molecular tests completed
Toronto, Dec. 29, 2020 (GLOBE NEWSWIRE) -- LifeLabs is pleased to announce that it has completed over 1 million COVID-19...
UPDATE — BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021
NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused...
Transactions in connection with share buyback program
Company announcement no. 53 - 2029 December 2020 Transactions in connection with share buyback program On 18 November 2020 NTG...
Capricor Therapeutics Announces DSMB Recommendation to Continue Phase II INSPIRE Trial for Severe COVID-19 Patients
Trial Assessing Ability of Capricor’s Cardiac Cell Therapy, CAP-1002, to Reduce the Cytokine Storm Associated with Severe COVID-19LOS ANGELES, Dec....
Model N Announces New Chief Financial Officer
SAN MATEO, Calif.--(BUSINESS WIRE)--$modeln--Model N, Inc. (NYSE: MODN), the leader in cloud revenue management solutions, today announced that John Ederer...
Hepion Pharmaceuticals Announces Positive Top Line Data for Low Dose CRV431 in Phase 2a ‘AMBITION’ Clinical Trial for Treatment of Advanced NASH
CRV431 Demonstrated to be Generally Safe and Well Tolerated Clinically Significant Reductions in Important Biomarkers, ALT and AST, Observed in...